Organon & Co. $OGN Stake Lessened by Sound Income Strategies LLC

Key Points

• Sound Income Strategies LLC has dramatically reduced its stake in Organon & Co. by 95.5%, selling off 633,795 shares in the second quarter, leaving them with 29,945 shares valued at $290,000.
• Organon reported $1.00 earnings per share for the last quarter, exceeding analysts' estimates of $0.94, despite a 0.8% decline in revenue compared to the previous year.
• The company announced a quarterly dividend of $0.02, resulting in an annual yield of 0.8% with a low payout ratio of 2.97%.

Sound Income Strategies LLC lowered its holdings in Organon & Co. (NYSE:OGN - Free Report) by 95.5% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 29,945 shares of the company's stock after selling 633,795 shares during the period. Sound Income Strategies LLC's holdings in Organon & Co. were worth $290,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Ransom Advisory Ltd purchased a new stake in shares of Organon & Co. in the first quarter valued at $32,000. Brooklyn Investment Group increased its stake in shares of Organon & Co. by 1,012.3% in the first quarter. Brooklyn Investment Group now owns 3,070 shares of the company's stock worth $46,000 after acquiring an additional 2,794 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S acquired a new position in shares of Organon & Co. in the first quarter worth $51,000. PARK CIRCLE Co increased its stake in shares of Organon & Co. by 640.7% in the first quarter. PARK CIRCLE Co now owns 4,000 shares of the company's stock worth $60,000 after acquiring an additional 3,460 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Organon & Co. in the first quarter worth $60,000. Hedge funds and other institutional investors own 77.43% of the company's stock.

Organon & Co. Trading Up 1.3%

NYSE OGN opened at $10.35 on Tuesday. Organon & Co. has a 1-year low of $8.01 and a 1-year high of $19.35. The company has a current ratio of 1.65, a quick ratio of 1.13 and a debt-to-equity ratio of 11.98. The company has a market capitalization of $2.69 billion, a PE ratio of 3.85, a price-to-earnings-growth ratio of 0.93 and a beta of 0.60. The firm's fifty day simple moving average is $9.79 and its 200-day simple moving average is $10.47.

Organon & Co. (NYSE:OGN - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $1.00 earnings per share for the quarter, topping analysts' consensus estimates of $0.94 by $0.06. Organon & Co. had a net margin of 11.15% and a return on equity of 163.88%. The business had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $1.55 billion. During the same period in the prior year, the business posted $1.12 earnings per share. Organon & Co.'s revenue for the quarter was down .8% compared to the same quarter last year. Organon & Co. has set its FY 2025 guidance at EPS. As a group, sell-side analysts anticipate that Organon & Co. will post 3.68 earnings per share for the current fiscal year.

Organon & Co. Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, September 11th. Stockholders of record on Friday, August 15th were paid a $0.02 dividend. The ex-dividend date of this dividend was Friday, August 15th. This represents a $0.08 dividend on an annualized basis and a dividend yield of 0.8%. Organon & Co.'s dividend payout ratio is 2.97%.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Want to see what other hedge funds are holding OGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Organon & Co. (NYSE:OGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.